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Abstract
Purpose To compare using immuno-PET/CT the distribution
of 89Zr-labelled rituximab without and with a preload of
unlabelled rituximab to assess the impact of preloading with
unlabelled rituximab on tumour targeting and radiation dose
of subsequent radioimmunotherapy with 90Y-labelled rituxi-
mab in CD20+ B-cell lymphoma.
Methods Five patients with CD20+ B-cell lymphoma and
progressive disease were prospectively enrolled. All patients
underwent three study phases: initial dosimetric phase with
baseline 89Zr-rituximab PET/CT imaging without a cold pre-
load, followed 3 weeks later by a second dosimetric phase
with administration of a standard preload (250 mg/m2) of
unlabelled rituximab followed by injection of 89Zr-rituximab,
and a therapeutic phase 1 week later with administration of
unlabelled rituximab followed by 90Y-rituximab. PET/CT im-
aging and tracer uptake by organs and lesions were assessed.
Results With a cold rituximab preload, the calculated whole-
body dose of 90Y-rituximab was similar (mean 0.87 mSv/MBq,
range 0.82–0.99mSv/MBq) in all patients.Without a preload, an
increase in whole-body dose of 59% and 87%was noted in two
patients with preserved circulating CD20+ B cells. This increase
in radiation dose was primarily due to a 12.4-fold to 15-fold
higher dose to the spleen without a preload. No significant
change in whole-body dose was noted in the three other patients
with B-cell depletion. Without a preload, consistently higher
tumour uptake was noticed in patients with B-cell depletion.
Conclusion Administration of the standard preload of
unlabelled rituximab impairs radioconjugate tumour targeting
in the majority of patients eligible for radioimmunotherapy,
that is patients previously treated with rituximab-containing
therapeutic regimens. This common practice may need to be
reconsidered and further evaluated as the rationale for this
high preload has its origin in the Bprerituximab era^.
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Introduction
Radioimmunotherapy (RIT) is the targeting of a monoclonal
antibody (mAb) coupled to a radioisotope to selectively deliv-
er ionizing radiation to tumours [1]. As lymphoma cells are
inherently radiosensitive, the CD20 antigen provides an ex-
cellent target for RIT because it is expressed at a high surface
density in most lymphomas [2]. Following RIT, both malig-
nant and normal B cells are depleted, with normal B cells
recovering within 6 months [3].
The most widely studied radioconjugates for the treatment
of B-cell non-Hodgkin’s lymphoma (NHL) are murine anti-
CD20 mAbs radiolabelled with 131I (tositumomab, Bexxar®;
GlaxoSmithKline, Brentford, UK; no longer available) or with
the pure β-emitting isotope 90Y (ibritumomab tiuxetan,
Zevalin®; Spectrum Pharmaceuticals Inc., Henderson, NV).
In Europe, only 90Y-ibritumomab has been licensed, and it is
used in combination with a preload of unlabelled rituximab
[4]. Several studies have shown the efficacy of RIT in patients
with CD20+)B-cell NHL, both as a single agent in indolent
lymphoma and in combination with chemotherapy in indolent
and aggressive lymphoma [3, 5–9]. Recently, the feasibility of
RIT with 90Y-rituximab using a 90Y-ibritumomab treatment
schedule has been reported [10].
As normal tissue toxicity (particularly myelosuppression) is
dose limiting for RIT, the therapeutic index for RIT is thought
to be enhanced by the use of excess unlabelled (Bcold^) anti-
bodies before RIT [2]. Preloading with unlabelled antibodies is
thought to prevent normal tissue toxicity by providing a more
predictable biodistribution profile of radiolabelled antibodies,
decreasing clearance rates and prolonging the circulating half-
life of the radiolabelled antibody [1, 11–13]. This preload is
assumed to clear the peripheral blood of B cells and enhance
targeting of the radiolabelled antibody to tumour cells. Despite
the common use of a preload of unlabelled antibodies before
RIT [14, 15], including its inclusion in clinical guidelines [4],
little is known about the potential impact of high levels of
circulating anti-CD20 antibodies on the targeting of a subse-
quent radiolabelled anti-CD20 antibody.
The further refinement of RIT has evolved to include con-
sideration of the use of immuno-PET technology in its appli-
cation [16]. Immuno-PET, the combination of PET and a
radiolabelled mAb, combines the high sensitivity and resolu-
tion of a PET camera with the specificity of a mAb [17, 18].
PET is better suited than SPECT to tracer quantification [17],
while targeting information can be combined with anatomical
information when PET/CT is used [19]. Apart from its
diagnostic capabilities and use in treatment planning,
immuno-PET has potential for quantification of molecular
interactions, which is particularly attractive when it is used
for simulation of subsequent antibody-based therapy.
The majority of available PET isotopes are not appropriate
for routine PET imaging because of unsuitable half-lives, poor
availability, high production costs, and poorly developed ra-
diochemistry [18]. 89Zr, which is a transition metal in group
IVB of the periodic table, decays by positron emission (frac-
tion 23 %) and electron capture (77 %) to 89Y. The concom-
itant gamma decay of 89Zr of 908.97 keV has no significant
influence on the quantitative accuracy of PET images because
these high-energy photons, with an energy far exceeding
511 keV, can be easily circumvented by the energy window
of the PET scanner. 89Zr has a half-life of 78.4 h, which is
compatible with the time needed for a mAb to achieve optimal
tumour-to-background ratios. 89Zr can be obtained in high
yield and radionuclide purity, and with low production costs.
Moreover, 89Zr has ideal characteristics for optimal image
quality and accurate quantification.
In what we be believe to be the first report of the use of
89Zr-rituximab, the aim of this study was to compare the dis-
tribution of 89Zr-rituximab with and without a standard pre-
load of unlabelled rituximab in patients with relapsed CD20+
B-cell lymphoma, with the aim of assessing the potential im-
pact of circulating anti-CD20 antibodies on whole-body dis-
tribution, radiation dose and tumour targeting of a subsequent
radiolabelled anti-CD20 antibody as part of a RIT regimen.
Materials and methods
Radioconjugate production
89Zr-Rituximab was produced in a Good Manufacturing Prac-
tice facility with a manufacturing license at the VU/VUmc cam-
pus (Amsterdam,Netherlands). 89Zr (2.7 GBq/mL in 1Moxalic
acid) was produced by the BV cyclotron using a (p,n) reaction
on natural 89Y and isolated using a hydroxamate column. The
starting point of the chelator was desferrioxamine B (Desferal®;
Novartis Pharma Stein AG, Stein, Switzerland), which was con-
verted to its succinylated form, N-succinyldesferrioxamine B
(N-sucDf). The hydroxamate groups of N-sucDf are temporar-
ily blocked with iron [Fe(III)], and the N-sucDf-Fe form was
esterifiedwith 2,3,5,6-tetrafluorophenol (TFP) to the bifunction-
al chelator, TFP-N-sucDf-Fe. Rituximab (Mabthera®; Roche,
Basel, Switzerland) was labelled with 89Zr starting from the
chelate, TFP-N-sucDf-Fe, as described previously [20]. In brief,
rituximab was modified by coupling of a Fe-N-sucDf-TFP ester
at room temperature (pH 9.5–9.7). The iron was then removed
from the chelate with an excess of ethylenediaminetetraacetic
acid at 35 °C (pH 4.2–4.5), and the modified protein was puri-
fied on a pyrogen-free PD-10 column. The modified rituximab
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was labelled with 89Zr by first neutralizing the pH of the 89Zr
solution with sodium carbonate and the protein was added to-
gether with 4-(2-hydroxyethyl)-1-piperazineethanesulphonic ac-
id buffer. After 60 min, the 89Zr-labelled protein was purified on
a pyrogen-free PD-10 column, and the product filtered. The im-
munoreactivity of 89Zr-rituximab was evaluated using a Lindmo
cell binding assay [21], using 0.1 % paraformaldehyde-fixed
NHL RAMOS cells, with an immunoreactive fraction above
70 % for each individual labelling procedure.
Study population
Five patients with CD20+ B-cell lymphoma and progressive
disease, and at least one prior treatment regimen were en-
rolled. Treatment with rituximab had to be stopped at least
6 months before inclusion.
Methodology
The study comprised three phases:
1. Diagnostic/dosimetric phase I: Baseline 89Zr-rituximab dy-
namic PET/CT imaging after injection of 89Zr-rituximab
(111 MBq) without a preload of unlabelled rituximab.
2. Diagnostic/dosimetric phase II (3 weeks later): Adminis-
tration of a standard preload (250 mg/m2) of unlabelled
rituximab followed 1 to 3 h later by injection of 89Zr-
rituximab and dynamic PET/CT imaging.
3. Therapeutic phase (1 week later): Administration of
250 mg/m2 of unlabelled rituximab followed by slow in-
travenous injection of 90Y-rituximab, using the same doses
as recommended for treatment with 90Y-ibritumomab
tiuxetan (Zevalin®; 0.3 mCi/kg, 11.1 MBq/kg, if platelet
count 100,000 to ≤150,000/mm3, 100 to ≤150×109/L; and
0.4mCi/kg, 14.8MBq/kg, if platelet count >150,000/mm3,
>150×109/L) [4].
PET/CT imaging
PET/CT scans were performed with a dedicated BGO PET
system coupled to a helical CT scanner (Discovery LS; GE
Healthcare Technologies, Milwaukee, WI), and PET/CT im-
ages were visualized on a dedicated viewing station (Advan-
tage Windows 4.5; GE).
PET with 89Zr-rituximab
Whole-body PETscans consisting of seven or eight bed positions
covering the patient from the base of the skull to the upper thighs
were obtained. At each bed position, a 5-min emission scan in
three-dimensional mode was acquired. Whole-body scans were
completed at three time-points starting within 1 h and at 72 h and
144 h after the first intravenous injection of 111MBq 89Zr-ritux-
imab. All scans were normalized and corrected for randoms,
scatter, attenuation and decay. The images (matrix 128×128)
were reconstructed using an attenuation and a normalization-
weighted ordered subsets expectation maximization (OSEM) al-
gorithm (Advance 6.0), with five iterations and 32 subsets
followed by postsmoothing of the reconstructed images using
an 8-mm full-width at half-maximum Gaussian filter.
CT scan
CT was performed in all patient studies at Blow dose^, without
administration of oral or intravenous contrast agent. The tube
current intensity used by the CT scanner was determined by
Auto-mA®, a dose-reduction algorithm provided by the camera
vendor that modulates the tube current intensity during acquisi-
tion depending on a noise index and the attenuation information
given by the planar scout image. The noise index for low-dose
CT scans was 28. The current intensity ranged from 30 to
200 mA, and the voltage was set to 120 kV. The whole-body
absorbed dose for the CT scans ranged between 3 and 5 mSv.
TheCTmapwas used for attenuation correction of the PETscans
and as a structural correlate to optimize PET image interpretation.
Contouring
Organs were contoured on the anatomical images obtained from
the CTscans using the DosiSoft® station. PET/CTcoregistration
was checked visually. The contours were then projected on the
PET images for statistical analysis. The considered organs (for
which residence times were calculated) were the liver, spleen,
bone marrow (skeleton), kidneys, lungs, gonads and thyroid.
The activity for calculating the residence times for the remainder
of the body was obtained from whole-body (head to thigh) vol-
umes of interest (VOIs), minus the sum of the activities of the
considered organs. The bone marrow activity was assessed by
automatic segmentation of the skeleton (excluding the skull)
performed on CT images using OWS® 1.0.
Several contouring methods were applied for the lesions
due to the great variability in visibility, both on CT and PET
images. When lesions were identifiable on PET images (i.e.
with an activity concentration higher than background activi-
ty), lesions were segmented with a fixed threshold of 42 % of
the maximum activity value. When there was an overlap be-
tween lesions, the CT images helped discriminate the different
lesions. When lesions were not identifiable on PET or auto-
mated segmentation was not reliable (i.e. because the contrast
was too low or because of proximity to organs with high
uptake), two options were possible: (1) if the lesion was clear-
ly identifiable on CT images, contours were drawn on the CT
images and then projected on the PET images; and (2) if the
lesion was not clearly identifiable on CT images, contours
were drawn on the day-6 PET images (where lesion contrast
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was often the highest) using the method described above, and
earlier PET images were then registered on the day-6 images
and the contours were projected, and manual corrections were
applied if registration was imperfect.
Quantification
The contours were exported in RT Structure format, then
imported into PMOD (PMOD Technologies Ltd, Zürich,
Switzerland) for quantification. The total activity (average ac-
tivity in a VOI multiplied by the volume) measured by PMOD
was divided by the injected activity (with decay correction)
resulting in the uptake percentage of organs and lesions.
Dosimetry
Dosimetry was performed using OLINDA/EXM®. For 89Zr
dosimetry, the time–activity curve (TAC) was plotted using
the activity values given by PMOD. For 90Y dosimetry, the
activity values were calculated from the 89Zr activities accord-
ing to the equation:
A90Y tacq
  ¼ A89Zr tacq





Where A90Y(tacq) and A89Zr(tacq) are the activities calculated
and measured, respectively, at the different acquisitions times,
tinj is the time of injection and t89Zr and t90Y are the half-lives
of the isotopes.
The total area under the TAC was calculated by summing
the following areas, with the following approximations: (1)
the area for the interval between time zero (injection) and time
1 (1 h after injection) calculated using a rectangle; (2) the area
between the three acquisition time-points calculated using
trapezoids between each time-point; and (3) the area after
the third time-point calculated using the physical decay. The
total area under the curve was then divided by the injected
activity (at time zero) to give the time-integrated activity co-
efficient, which was inputted into OLINDA/EXM® (resi-
dence times for each considered organ are available in the
Supplementary Online Table 1).
.
Results
Patient characteristics are shown in Table 1. Five patients with
CD20+ B-cell lymphoma with progressive disease and who
had at least one prior treatment regimen were enrolled. Four
patients were treated for a relapse of follicular lymphoma and
one for a nodular lymphocyte-predominant, CD20+
Hodgkin’s lymphoma. None of the patients had bone marrow
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(range 41–62 years) and all were male. The median number of
previous treatment lines was three (range one to four). The two
patients with fewer than three previous treatments (patients 1
and 2) had preserved circulating CD20+ lymphocytes
(assessed by immunophenotyping in the blood before inclu-
sion in this study), while the other three patients had B-cell
depletion (patients 3, 4 and 5) due to three or more prior
treatment lines (although immunophenotyping was not avail-
able for patient 4, this patient was considered to have B-cell
depletion having been previously treated with autologous stem
cell transplantation and RIT). A detailed overview of the ef-
fective and absorbed doses for 89Zr-rituximab and 90Y-rituxi-
mab is available in the Supplementary Online Tables 2–5.
With a preload of unlabelled rituximab, the calculated ef-
fective (whole-body) doses for 90Y-rituximab were similar in
all patients (mean 0.87 mSv/MBq, range 0.82–0.99 mSv/
MBq). Without a preload, the whole-body radiation doses
were 59 % and 87 % higher than with a preload in patients 1
and 2, respectively, but were not significantly different in the
three other patients (Fig. 1).
The higher whole-body radiation doses without a preload
in patients 1 and 2 were primarily due to higher radiation
doses to the spleen (Fig. 2). Without a preload of rituximab,
the uptake of the radioconjugate, 90Y-rituximab, was 12.4-fold
to 15-fold higher in these two patients and only 1.1-fold to
2.4-fold higher in the other three patients. Correlation with the
number of previous treatment lines in each patient showed that
the higher tracer uptake in the spleen, and hence the higher
whole-body radiation dose, was much higher in the two pa-
tients who had had only one or two previous treatment regi-
mens, and was only moderately higher in the three patients
who had three or four previous treatment regimens. Correla-
tion of the percentage of circulating B cells revealed that the
influence of a preload of rituximab on the distribution of the
radioconjugate, especially uptake in the spleen, depended
highly on the amount of uptake of circulating CD20+ lympho-
cytes in the spleen (Fig. 3). A major influence of the preload is
noted in the two patients with preserved (5–9 %) circulating
CD20+ lymphocytes, while only a minor influence on the
radiation dose to the spleen was seen in patients with B-cell
depletion (0 % circulating CD20+ lymphocytes).
Without a preload, the radiation doses to the bone marrow
were 9% to 58% higher than with a preload (Fig. 4), while the
radiation doses to the liver were similar with and without a
preload (Fig. 5).
For 89Zr-rituximab, the calculated effective (whole-body)
doses after a preload of unlabelled rituximab were similar in
all patients (mean 0.41 mSv/MBq, range 0.39–0.44 mSv/
MBq).Without a preload, the whole-body radiation doses were
37 % and 55 % higher than with a preload in the two patients
with preserved circulating CD20+ lymphocytes, primarily due
to higher radiation doses to the spleen, but were not significant-
ly different in the three patients with B-cell depletion (Table 2).
Comparison of the maximum standardized uptake value
(SUVmax) of the 30 lesions in the five patients (Fig. 6) using
the 89Zr-rituximab immuno-PET/CT images taken 6 days after
injection showed a consistently higher lesion uptake (tumour
targeting) without a preload in all three patients with B-cell
depletion (as illustrated in patient 4 in Fig. 7). In the two
patients with preserved circulating CD20+ lymphocytes, three
lesions showed less or no uptake without a preload, while
other lesions showed higher uptake. A more detailed evalua-
tion of these three lesions with low uptake revealed the rea-
sons for this finding. In patient 1 (with 9 % circulating CD20+
lymphocytes) with the preload, uptake in an involved lymph
node was higher as a result of lower uptake in the spleen
leading to a higher residence time of the tracer in the blood
circulation. Images obtained without the preload showed in-
tense uptake in the spleen and fast clearance of the injected
tracer from the blood 1 h after 89Zr-rituximab injection
(Fig. 8). In patient 2 (with 5 % circulating CD20+ lympho-
cytes) with the preload, tracer uptake in involved lymph nodes
was lower on the one hand, but on the other hand was higher
in the two visceral lesions as a result of lower uptake in the
spleen leading to a higher residence time of the tracer in the
blood circulation and binding of the radioconjugate in less
1 2 3 4 5
Without predosing 1.856 1.393 0.849 0.804 0.808



























Whole Body Dosimetry 90Y-rituximab 
Fig. 1 Whole-body dosimetry of 90Y-rituximab with and without a
preload of unlabelled (Bcold^) rituximab antibodies
1 2 3 4 5
Without predosing 51 20.6 3.09 2.62 2.78






















Spleen Dosimetry 90Y-rituximab 
Fig. 2 Radiation dose to the spleen as a function of the amount of
circulating CD20+ lymphocytes
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accessible regions (Fig. 9). The pharmacokinetics of 89Zr-ri-
tuximab confirmed the fast clearance of 89Zr-rituximab from
the blood in both patients (particularly patient 1) with pre-
served circulating CD20+ lymphocytes without preload and
the significantly slower clearance of the radioconjugate (com-
parable with the clearance in patients with B-cell depletion)
with a preload (Fig. 10).
Discussion
The efficacy of RIT in patients with B-cell NHL as a single
agent in indolent lymphoma and in combination with chemo-
therapy in both indolent and aggressive lymphoma has been
reported [3, 5–9]. The anti-CD20 antibodies, 90Y-
ibritumomab tiuxetan and 131I-tositumomab, are the only
radiolabelled antibodies licensed for RIT, with 90Y-
ibritumomab tiuxetan being currently the only commercially
available agent.
There is interest in developing a RIT regimen incorporating
radiolabelled rituximab, which is part of the standard of care in
NHL [22–25]. Rituximab is a chimeric IgG1 kappa mAb
targeting the same epitope on the CD20 antigen as the murine
mAb ibritumomab, and which is predicted to increase
immune-based antitumour activity, improve pharmacokinetics
and reduce immunogenicity compared to currently available
radioconjugates. RIT with 90Y-rituximab in CD20+ B-cell
lymphoma has shown promising efficacy and tolerability
when utilizing the 90Y-ibritumomab tiuxetan schedule [10].
The efficacy of RIT is dependent on the properties of the
targeted antigen (i.e. specificity, tumour selectivity, density,
availability, shedding, heterogeneity of expression), the prop-
erties of the tumour (i.e. vascularization, blood flow, perme-
ability), the properties of the antibody, and the properties of
the radioisotope (i.e. emission characteristics, half-life, bio-
availability) [14, 26]. The therapeutic index of RIT is thought
to be improved if it is preceded by administration of excess
cold antibodies that prolongs the circulating half-life of the
radiolabelled antibody and blocks nonspecific binding to nor-
mal tissues resulting in increased tumour retention of the
radiolabelled antibody [12, 14].
Despite the common use of a preload of cold antibodies
before RIT [4], little is known about the potential impact of
such high levels of circulating anti-CD20 antibodies on tu-
mour targeting of a subsequently administered radiolabelled
anti-CD20 antibody. This common practice is based on a
Fig. 3 89Zr-rituximab immuno-
PET images obtained 6 days after
injection in a patient (patient
2; anterior view) with a preserved
amount of circulating CD20+
lymphocytes and a patient
(patient 3; posterior view) with B-
cell depletion
1 2 3 4 5
Without predosing 1.89 2.73 1.79 1.39 1.88























Bone Marrow 90Y-rituximab 
Fig. 4 Influence of a preload of unlabelled rituximab on the radiation
dose to the bone marrow
1 2 3 4 5
Without predosing 2.68 2.46 1.92 2.01 2.86
























Liver dosimetry 90Y-rituximab  
Fig. 5 Influence of a preload of unlabelled rituximab on the radiation
dose to the liver
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small phase 1/2 dosimetry study using 111In-labelled
ibritumomab tiuxetan planar imaging in six patients [27]. In
three of these patients, a preload of 100 mg/m2 rituximab was
administered, while the other three patients received 250 mg/
m2. The 250 mg/m2 rituximab dose was chosen as the dose to
be given before RIT because no difference in imaging or do-
simetry was observed between dosing groups, and there was
potential for enhanced clinical response from the higher dose
of rituximab. However, no comparison has been made on the
distribution without a predose of unlabelled antibodies. Fur-
thermore, the study evaluated the impact of a preload with
chimeric antibodies (rituximab) on targeting of a second
radiolabelled murine anti-CD20 antibody (ibritumomab).
To the best of our knowledge, our study is the first to
compare the distribution of 89Zr-rituximab with and without
a standard preload of unlabelled rituximab in patients with
relapsed CD20+ B-cell lymphoma. Although this study was
conducted in a small group of patients, striking differences in
the influence of the standard preload dose of unlabelled ritux-
imab (250 mg/m2) between patients with and without B-cell
depletion were observed. In patients with B-cell depletion,
which represents themajority of patients currently treated with
RIT, the preload of unlabelled rituximab had no significant
influence on whole-body radiation dose, yet consistently im-
paired tumour targeting due to a partial saturation of CD20
receptors present on lymphoma cells. In contrast, in the two
patients with preserved circulating CD20+ lymphocytes, the
preload of unlabelled rituximab cleared circulating B lympho-
cytes from the blood, reduced whole-body radiation dose,
significantly reduced radioactivity uptake in the spleen, and
resulted in slower clearance of the radioconjugate from the
circulation.
The preload of cold rituximab consistently impaired tu-
mour targeting in the three patients with B-cell depletion. In
contrast, it had a variable influence on tumour targeting in the
two patients with preserved circulating CD20+ lymphocytes,
Table 2 Absorbed doses to the liver, spleen and red marrow, and effective whole-body dose for 89Zr-rituximab
Without preload With preload
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Mean±SD Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Mean±SD
Liver (mGy/MBq) 1.13 1.08 0.86 0.89 1.21 1.03±0.15 1.22 0.95 0.97 0.95 0.94 1.01±0.12
Red marrow
(mGy/MBq)
0.59 0.79 0.59 0.50 0.62 0.62±0.11 0.54 0.58 0.53 0.48 0.54 0.53±0.03
Spleen
(mGy/MBq)
12.30 5.35 0.98 0.89 0.92 4.09±4.97 1.10 0.65 0.93 0.53 0.53 0.75±0.26
Whole body
(mSv/MBq)
































Uptake with preload (SUVmax)
Lesion uptake (SUVmax) 
without versus with a preload of unlabelled 
antibodies
Patients 1-2; preserved circulating B-cells
patients 3-5 with B-cell depletion
Fig. 6 Comparison of lesion
uptake (SUVmax) without and
with a preload of unlabelled
rituximab
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enhancing uptake in three lesions (of which two were visceral)
by improving biodistribution and preventing sequestration of
the radioconjugate by the antigen sink, while impairing
targeting of other tumour sites due to partial saturation with
unlabelled rituximab.
Although clinical studies have shown that high and even
multiple doses of induction therapy with rituximab alone or as
part of rituximab-containing chemotherapy regimens do not
appear to compromise the clinical efficacy of subsequent anti-
CD20-based RIT [28–30], and that high serum levels of ritux-
imab significantly increase the effective half-life of subse-
quent radiolabelled rituximab [29], the key issue of the opti-
mal treatment approach for RIT remains to be elucidated. New
treatment approaches, such as fractionated RIT [29, 31] or
dual-targeted antibody/radioantibody therapy [32], have the
potential to further improve the clinical efficacy of RIT. A
recent phase I study [33] has shown encouraging results in
patients with relapsed/refractory aggressive lymphoma using
a fractionated dosing schedule along with the dual-targeting
approach with the intention of improving the delivery and
retention of the radioconjugate at the tumour sites. In that
study, unlabelled anti-CD20 veltuzumab was administered to
deplete the circulating B cells, enhancing biodistribution of
the anti-CD22 radioconjugate 90Y-epratuzumab tetraxetan
without interfering with tumour targeting.
The inherent heterogeneity of radiopharmaceutical distri-
bution in target lesions and normal organs suggests that a
individualized patient-tailored approach might be of addition-
al value in RIT. The antigen sink, which depends on several
parameters such as tumour burden, spleen volume and amount
of circulating B-lymphocytes, plays a key role in the amount
of rituximab needed to ensure adequate serum levels (effective
half-life) of the radioconjugate. Other factors influencing
Without preload With preload
89 Zr-rituximab Immuno-PET/CT 6d 
Fig. 7 89Zr-rituximab immuno-PET/CT images in patient 4 (with
CD20+ B-cell depletion) obtained 6 days after injection without and
with a preload of unlabelled rituximab show consistently better tumour
targeting without the preload
Fig. 8 18F-FDG PET and
89Zr-rituximab immuno-PET
images in patient 1 obtained 1 h
after injection and 6 days after
injection without a preload of
unlabelled rituximab and 6 days
after injection with a preload of
unlabelled rituximab show higher
uptake in the involved lymph
node with the preload as a result
of a higher residence time of the





without preload      with preload
Fig. 9 18F-FDG PET/CTand 89Zr-rituximab immuno-PET/CT images in
patient 2 obtained 6 days after injection with and without a preload of
unlabelled rituximab show lower tracer uptake in involved lymph nodes
with the preload (white arrows), but higher uptake in less accessible
visceral lesions (oesophagus and stomach; blue arrows) resulting in
better tumour targeting
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tumour targeting by the radioconjugate are tumour heteroge-
neity and site of tumour involvement. Adequate receptor im-
aging might be a promising tool for the evaluation of the
influence of these multiple factors on tumour targeting, for
imaging-based three-dimensional calculation of the absorbed
dose for organs and lesions, and for simulation of different
treatment approaches. In the five patients in this study a pre-
load of rituximab improved the biodistribution of the
radioconjugate by preventing its sequestration in patients with
preserved circulating CD20+ lymphocytes, but consistently
impaired radioconjugate tumour targeting in patients with B-
cell depletion, the latter representing the majority of patients
eligible for RIT in the Brituximab era^. However, the small
number of patients in this study along with the multiple pa-
rameters influencing tumour targeting in RIT in CD20+ lym-
phoma do not allow drawing definitive conclusions
concerning the optimal treatment approach in RIT to be
drawn, and this should be the basis of further studies.
The advantage of using a positron-emitting isotope is that
PET is inherently quantitative, whereas quantification with
planar imaging involves considerable uncertainties that can
often be greater than estimated activity concentrations. 89Zr-
rituximab PET/CT, as assessed in our study, provides an ex-
cellent imaging tool for accurate quantification of CD20 anti-
gen expression, which is of particular interest for dosimetry as
a prelude to RIT with 90Y-rituximab, allowing the possibility
for dose–response correlation, prediction of treatment out-
come, better selection of patients for receptor-targeted therapy,
and patient-tailored image-guided therapy [17, 34–36].
The effective patient dose of 89Zr-rituximab (after a preload
of unlabelled rituximab) was relatively high (0.41 mSv/MBq),
probably due to the long half-life of the tracer and concomitant
gamma decay of 89Zr of 908.97 keV. In this study we admin-
istered 111 MBq 89Zr-rituximab that resulted in an average
total effective dose of 45.5 mSv, which is justifiable within
the context of subsequent RIT with administration of
14.8 MBq/kg of 90Y-rituximab (1,184MBq for a body weight
of 80 kg), resulting in an average total effective dose of
1.03 Sv for RIT. Nevertheless, given the high image quality
with 111 MBq in this study and the high sensitivity of new-
generation (time-of-flight) PET scanners, lowering the
injected activities to 74 MBq (or less by increasing the acqui-
sition time, especially on day 6 after injection) while preserv-
ing the largely sufficient quantitative image accuracy should
be feasible.
As there are currently no dosimetry data available for
90Y-rituximab, the doses were compared with those of
Fig. 10 Pharmacokinetics. After intravenous administration of 111 MBq
89Zr-rituximab, blood samples were obtained from the arm opposite the
infusion side 10min, 1 and 2 h, and then 1, 3 and 6 days after infusion. At
each time-point, 89Zr disintegration counts/unit volume were measured
using a calibrated γ-well counter corrected for 89Zr physical decay. a
Clearance half-life of 89Zr-rituximab with and without predosing. b, c
Blood concentration of 89Zr-rituximab expressed as percentages of the
initial 10-min value in (b) patients 1 and 2 with preserved circulating
CD20+ lymphocytes and (c) patients 3, 4 and 5 with B-cell depletion
Table 3 Comparison of doses of 90Y-rituximab and 90Y-ibritumomab (after a preload of rituximab) for selected organs using 89Zr-immuno-PET
Study Radioconjugate Absorbed organ doses (mGy/MBq, mean±SD) Effective whole-body dose
(mSv/MBq, mean±SD)
Liver Spleen Kidneys Lungs Red marrow
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90Y-ibritumomab (the murine counterpart, binding the same
epitope) [34], both after a preload of rituximab and using
89Zr-immuno-PET. The calculated mean effective dose was
the same for both studies (0.87 mSv/MBq). Compared with
the current study, the mean absorbed doses of 90Y-
ibritumomab in the liver and spleen tend to be higher and
those for kidneys and lungs somewhat lower (Table 3). The
mean absorbed dose of 90Y-rituximab to the red marrow
was threefold higher. Although some differences in phar-
macokinetics between the two mAbs may be expected, it is
more likely that the discrepancy in the absorbed doses are
due to differences in methodology between studies. The
major difference in methodology is for the assessment of
the dose to the red marrow. In the current study, a novel
three-dimensional image-based approach was used for
assessing the bone marrow dose, while for the 89Zr-/90Y-
ibritumomab study, red marrow dosimetry was based on
blood samples, where the residence time was estimated
assuming a red marrow radioactivity concentration of
30 % of the whole-blood activity concentration [37]. The
latter approach may underestimate the red marrow dose if
there is any interaction of the targeting agent with the bone
marrow.
The similar haematological toxicities (and efficacy) after
90Y-rituximab (using the Zevalin® treatment schedule) in the
present study (Table 1) and a previous study [10] support the
assumption that the threefold higher mean absorbed dose of
90Y-rituximab to the red marrow compared to that of 90Y-
ibritumomab was more likely due to differences in methodolo-
gy than to higher accumulation of the chimeric radioconjugate
in the bone marrow. Another difference in methodology be-
tween the two studies is that the organ VOIs in the current study
were drawn on the anatomical images obtained from the
coregistered CT images (using PET/CT), while in the
89Zr-/90Y-ibritumomab study the images were acquired on a
stand-alone PET scanner with the organs contoured on func-
tional images. Finally, in the current study, whole-body VOIs
(not including part of the legs) were used for calculating the
residence times for the remainder of the body, that somewhat
underestimated the effective whole body doses. However, this
would not have affected the calculated absorbed organ doses of
90Y-rituximab, as the deposition of the energy of the radiation
emitted by 90Y is limited to the organ only.
In conclusion, the results of our study show that the admin-
istration of the standard preload of unlabelled rituximab im-
pairs tumour targeting of the radioconjugate in the majority of
patients eligible for RIT, primarily patients with B-cell deple-
tion due to prior treatment with rituximab-containing thera-
peutic regimens. As the rationale for this high predose has its
origin in the Bprerituximab era^, this common practice may
need to be reconsidered and further evaluated, in particular in
the different setting of the licensed radioconjugate 90Y-
ibritumomab tiuxetan (Zevalin®), where a chimeric antibody
(rituximab) is used as a preload for subsequent RIT with a
second radiolabelled murine anti-CD20 antibody
(ibritumomab). Our observations also suggest that imaging
with a mAb labelled with a positron-emitting isotope, such
as 89Zr, in combination with PET could be useful for visual-
izing the biodistribution of the individual radiotracer, and may
have utility in the elucidation of the dose–response of RITand
in defining patients at high risk of toxicity. Further investiga-
tion is warranted to confirm the potential role of immuno-PET
in receptor-targeted therapies.
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